Vetoquinol SA VETO
EURONEXT · France · Health Technology
€75.10-0.80 (-1.05%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
LURE, France, September 10, 2026--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated: "The results for the first half of fiscal year 2026 confirm the strength of our business model, with a return to growth in our business, strong momentum for our Essential products, rising profitability, and robust cash flow generation. We are actively preparing our next growth drivers, with several new product launches on the horizon."
Recent Performance Snapshot Without a specific news catalyst, interest in Vetoquinol (ENXTPA:VETO) today largely centers on how the stock’s mixed recent returns line up with its current earnings profile and its annual growth in revenue and net income. See our latest analysis for Vetoquinol. At a share price of €76.1, Vetoquinol has a 1-year total shareholder return of 5.64%, while its 90 day share price return of an 11.1% decline suggests recent momentum has been fading after earlier...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.